EcoDrugPlus

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSPREG00000011064
Gene Symbol: NFKB1
4 Cross references
200 Possible Orthologues:

Nuclear Factor, Erythroid 2 Like 2

Ensembl ID : ENSPREG00000005434
Gene Symbol: NFE2L2
3 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSPREG00000004255
Gene Symbol: NR1H3
3 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSPREG00000017870
Gene Symbol: NR1H4
3 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSPREG00000005578
Gene Symbol: NR3C1
4 Cross references
205 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSPREG00000023228
Gene Symbol: NR3C2
3 Cross references
209 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSPREG00000006956
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSPREG00000008437
Gene Symbol: OPRD1
3 Cross references
179 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSPREG00000006708
Gene Symbol: OPRK1
2 Cross references
197 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSPREG00000009390
Gene Symbol: OXTR
3 Cross references
191 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSPREG00000003635
Gene Symbol: OXTR
3 Cross references
183 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSPREG00000019697
Gene Symbol: PAK4
3 Cross references
166 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).